Jobs Go At Shield Therapeutics As Failed Study Fallout Hits
Executive Summary
Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.
You may also be interested in...
Keeping Track: Turalio, Nubeqa And Accrufer Mark Trio Of Novel Drug Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Some Calm Before The Storm
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
The latest drug development news and highlights from our US FDA Performance Tracker.